|
||||||||||||||||||||||
|
|
Chemotherapy with Anguidine for CNS Tumors in Children
Basic Trial Information
Objectives I. Determine the antitumor activity of anguidine in the treatment of malignant gliomas relative to clinical response and survival. II. Observe for expected and unexpected adverse effects and for factors important in producing these effects. III. Determine the antitumor activity of anguidine in the treatment of malignant brain tumors in children and adolescents relative to clinical response and survival. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with histologically confirmed primary CNS tumors: astrocytoma, Grades III and IV; ependymoma; oligodendroglioma; medulloblastoma, or patients under 21 years of age with recurrent brain stem glioma. They must have a life expectancy of at least 8 weeks, granulocyte counts over 2000, platelet counts at least 100,000 and a lesion measurable by scan. They must not have had radiation or chemotherapy for at least 3 weeks. Serum creatinine must not exceed 2.5 mg, nor bilirubin 6.0 mg. (Protocol closed to adults in February 1980 and replaced, for adults, by SWOG-7980. Protocol closed to patients with astrocytoma in February 1980.) Expected Enrollment A minimum of 14 patients will be entered in each stratification. Protocol closed March 1982. Outline Nonrandomized study. Single-agent Chemotherapy. Anguidine, ANG, NSC-141537. Trial Lead Organizations Pediatric Oncology Group
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |